Overview

Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

Status:
Terminated

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

Summary

This study is to assess the efficacy and safety of two doses of ondansetron (0.5 mg and 0.75 mg) relative to placebo when administered twice daily as adjunctive therapy for adult patients with Obsessive-Compulsive Disorder (OCD) who have not adequately responded to treatment with a serotonin reuptake inhibitor (SRI).

Phase:

Phase 2

Details

Lead Sponsor:

Transcept Pharmaceuticals

Treatments:

Ondansetron
Serotonin
Serotonin Uptake Inhibitors